WHO Plays Central Role In Shaping R&D Agenda For Antimicrobial Resistance

The Lancet: The drugs don’t work: WHO’s role in advancing new antibiotics
Peter Beyer, senior adviser in the Department of Essential Medicines and Health Products at the WHO, and colleagues

“…With its research and development blueprint for action to prevent epidemics, WHO has set out how to identify priority pathogens, develop global roadmaps on research priorities, and support national research capacities. … WHO has an indispensable role in research and development in antimicrobial resistance where there is a compelling unmet public health need for new products. [WHO’s activities to shape the research and development agenda for antimicrobial resistance] will form part of the future Global Development and Stewardship Framework to combat antimicrobial resistance that WHO, the Food and Agriculture Organization of the United Nations, and the World Organisation for Animal Health (OIE) are developing in line with the mandate provided by the U.N. High-Level Declaration on Antimicrobial Resistance. This work will also inform work of the Ad-Hoc Interagency Coordination Group on Antimicrobial Resistance which will report back to the U.N. General Assembly in 2019 on how to ensure sustained effective global action to address antimicrobial resistance” (7/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.